Ann: ACTION3 IND Approved in China, page-148

I’d be interested to know what others think, but DMX-200 works in conjunction with Angiotensin Receptor Blockers (ARBS) to magnify their effects - It’s not a standalone treatment.

Therefore, if it does improve the efficacy of ARBS, and we are comparing DMX-200 + ARB vs just an ARB (Placebo current best standard of care), then we should see a greater effect on the eGFR slope with DMX-200 vs placebo? IE we are not comparing an ARB vs ARB effect on eGFR slope which is likely not statistically different enough from one another?

The other issue with Spartensan is its primary end point was eGFR slope, which it failed to meet in its phase 3 trial. I also remember that it carries a black box warning, meaning that it has highly adverse effects warnings, which could be a reason for FDAs reason for declining accelerated approval. DMX-200 has an excellent safety profile.

Just my thoughts, would be great to hear what others think!